RSV LID cp ΔM2-2 Vaccine

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Respiratory Syncytial Virus Infections

Phase 1

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age

TerminatedNCT02890381

National Institute of Allergy and Infectious Diseases (NIAID)Respiratory Syncytial Virus Infections

Start: 2016-10-05End: 2017-04-24Updated: 2021-11-05

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

TerminatedNCT02948127

National Institute of Allergy and Infectious Diseases (NIAID)Respiratory Syncytial Virus Infections

Start: 2016-09-30End: 2018-04-30Updated: 2018-08-17

Related Papers

Live-Attenuated Respiratory Syncytial Virus Vaccine With Deletion of RNA Synthesis Regulatory Protein M2-2 and Cold Passage Mutations Is Overattenuated

Open Forum Infectious Diseases2019-05-0623 citations